The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
|Videos|March 26, 2021
Dr. Berdeja on FDA Approval of bb2121 in Relapsed/Refractory Multiple Myeloma
Author(s)Jesus G. Berdeja, MD
Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma.
Advertisement
Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5